The Potential Prognostic Value of Dual-Imaging PET Parameters Based on 18F-FDG and 18F-OC for Neuroendocrine Neoplasms

IF 2.8 4区医学 Q2 Medicine

Molecular Imaging Pub Date : 2022-03-17 DOI:10.1155/2022/6511179

Jiale Hou, T. Long, Yi Yang, Dengming Chen, Shuo Hu

{"title":"The Potential Prognostic Value of Dual-Imaging PET Parameters Based on 18F-FDG and 18F-OC for Neuroendocrine Neoplasms","authors":"Jiale Hou, T. Long, Yi Yang, Dengming Chen, Shuo Hu","doi":"10.1155/2022/6511179","DOIUrl":null,"url":null,"abstract":"Background To identify parameters based on dual-imaging 18F-AlF-NOTA-octreotide (18F-OC) and 18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) for predicting the prognosis of neuroendocrine neoplasms (NENs). Materials and Methods Sixty-six patients (age: mean ± standard deviation (SD): 51.8 ± 11.8 years) who underwent both 18F-OC and 18F-FDG PET/CT imaging were enrolled in our retrospective study. The following PET parameters were measured: the maximum standardized uptake value (SUVmax) and the volumetric parameters—18F-OC SSR-derived tumor volume (TV) and somatostatin receptor expression (SRE, TV multiplied by the mean standardized uptake value (SUVmean)) and the 18F-FDG-derived multiple tumor volume (MTV) and tumor lesion glycolysis (TLG). The NETPET grade based on dual-imaging PET images was assessed. Progression-free survival (PFS) was set as an endpoint. Univariate and multivariate survival analyses were performed for PET parameters and clinical tumor data. Results In the univariate survival analyses of clinical information, PFS was significantly associated with age (>45.5 vs ≤45.5, years, P < 0.034) and the presence of bone metastases (P = 0.04). Higher values for the 18F-FDG and 18F-OC volumetric parameters and the NETPET grade were adverse factors for PFS according to the dual-imaging PET parameters. In the multivariate survival analysis, the NETPET grade and SRE were predictors of PFS in NEN patients. Conclusion The NETPET grade is a potential noninvasive prognostic biomarker for NENs.","PeriodicalId":49796,"journal":{"name":"Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/6511179","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 3

Abstract

Background To identify parameters based on dual-imaging 18F-AlF-NOTA-octreotide (18F-OC) and 18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) for predicting the prognosis of neuroendocrine neoplasms (NENs). Materials and Methods Sixty-six patients (age: mean ± standard deviation (SD): 51.8 ± 11.8 years) who underwent both 18F-OC and 18F-FDG PET/CT imaging were enrolled in our retrospective study. The following PET parameters were measured: the maximum standardized uptake value (SUVmax) and the volumetric parameters—18F-OC SSR-derived tumor volume (TV) and somatostatin receptor expression (SRE, TV multiplied by the mean standardized uptake value (SUVmean)) and the 18F-FDG-derived multiple tumor volume (MTV) and tumor lesion glycolysis (TLG). The NETPET grade based on dual-imaging PET images was assessed. Progression-free survival (PFS) was set as an endpoint. Univariate and multivariate survival analyses were performed for PET parameters and clinical tumor data. Results In the univariate survival analyses of clinical information, PFS was significantly associated with age (>45.5 vs ≤45.5, years, P < 0.034) and the presence of bone metastases (P = 0.04). Higher values for the 18F-FDG and 18F-OC volumetric parameters and the NETPET grade were adverse factors for PFS according to the dual-imaging PET parameters. In the multivariate survival analysis, the NETPET grade and SRE were predictors of PFS in NEN patients. Conclusion The NETPET grade is a potential noninvasive prognostic biomarker for NENs.

查看原文本刊更多论文

基于18F-FDG和18F-OC的双显像PET参数对神经内分泌肿瘤的潜在预后价值

目的探讨基于18F-AlF-NOTA-octreotide (18F-OC)和18-氟脱氧葡萄糖(18F-FDG)正电子发射断层扫描(PET)的双成像参数对神经内分泌肿瘤(NENs)预后的预测价值。材料与方法回顾性研究66例同时行18F-OC和18F-FDG PET/CT显像的患者(平均±标准差(SD): 51.8±11.8岁)。PET测量如下参数:最大标准化摄取值(SUVmax)和体积参数- 18f - oc ssr衍生的肿瘤体积(TV)和生长抑素受体表达(SRE, TV乘以平均标准化摄取值(SUVmean))和18f - fdg衍生的多重肿瘤体积(MTV)和肿瘤病变糖酵解(TLG)。基于双成像PET图像评估NETPET分级。无进展生存期(PFS)作为终点。对PET参数和临床肿瘤数据进行单因素和多因素生存分析。结果在临床信息的单因素生存分析中，PFS与年龄(bb0 45.5 vs≤45.5，年龄，P < 0.034)和是否存在骨转移相关(P = 0.04)。根据双成像PET参数，较高的18F-FDG和18F-OC体积参数和NETPET分级是PFS的不利因素。在多变量生存分析中，NETPET分级和SRE是NEN患者PFS的预测因子。结论NETPET分级是NENs潜在的无创预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging 生物-核医学

CiteScore

4.50

自引率

3.60%

发文量

审稿时长

>12 weeks

期刊介绍： Molecular Imaging is a peer-reviewed, open access journal highlighting the breadth of molecular imaging research from basic science to preclinical studies to human applications. This serves both the scientific and clinical communities by disseminating novel results and concepts relevant to the biological study of normal and disease processes in both basic and translational studies ranging from mice to humans.